Fusion Antibodies

18 results

Fusion chief executive Paul Kerr welcomed the company’s interim results on Friday.
Revenue up 9% at Fusion Antibodies despite pandemic

Revenue at Belfast biotech company Fusion Antibodies increased by 9 per cent in the six months up to September 30th despite the challenges posed by th(...)

Dr Paul Kerr, chief executive Fusion Antibodies. “We are leveraging our antigen expertise to create multiple antigens to be used against the Covid-19 pandemic”
Fusion shares soar on news of antigens for Covid-19 tests

Shares in Northern Ireland pharmaceutical research company Fusion Antibodies soared on Friday after the company said it had developed high-purity anti(...)

Fusion Antibodies said it is positive about the coming 12 months.
Fusion Antibodies sees annual revenues rise almost 80%

Northern Ireland pharmaceutical contract research company Fusion Antibodies said full-year revenues rose almost 80 per cent in the year to the end of (...)

In April, Fusion raised £3m following a share sale. Since then it has generated Covid-19 antigens or molecules capable of stimulating an immune response. Photograph: iStock
Fusion Antibodies sees revenues rise almost 80%

Northern Ireland contract research company Fusion Antibodies said revenues for the year to the end of March will be almost 80 per cent higher than the(...)

Established in 2001, Fusion provides a range of antibody engineering services for the development of antibodies for both therapeutic drug and diagnostic applications.
Fusion Antibodies gets green light from investors for £3m rights issue

Fusion Antibodies, a Belfast-based contract research firm, has secured shareholder approval for a €3 million rights issue. The London-listed company,(...)

Fusion Antibodies will use the funds to expand its antibody library.
Fusion Antibodies announces £3m share placing to help fund Covid-19 work

Northern Ireland contract research company Fusion Antibodies has announced a £3 million share placing to expand its mammalian antibody library to incl(...)

Covid-19 pandemic has ‘limited impact’ on Fusion Antibodies

Northern Ireland contract research company Fusion Antibodies has so far had a “very limited impact” from the Covid-19 pandemic, with the company remai(...)

The company, listed on London’s AIM exchange, said trading in its financial third quarter continued the favourable trends seen in the first half of the year. Photograph: iStock
Revenues to be ‘materially ahead’ of previous year at Fusion Antibodies

Northern Ireland contract research company Fusion Antibodies posted a positive trading update on Wednesday, forecasting full year revenues to come in (...)

Fusion Antibodies is confident of significant revenue growth in the second half of the year
Fusion Antibodies sees revenue continue to grow

Fusion Antibodies, a pharmaceutical contract research company with its headquarters in Belfast, said revenue continued to grow in the six months to th(...)

Belfast research contract group Fusion Antibodies reported record second-half revenues as it moves past AIM-listing pressures.
Fusion Antibodies sees full year revenues dip 19%

Northern Ireland contract research company Fusion Antibodies recorded a 19 per cent fall in full year revenues to £2.2 million on the back of a weak f(...)

  • 1
  • 2
  • Next ›
  • Last »